Targeted Resequencing of Epilepsy Genes: A Pharmaco-Therapeutic Perspective

Anna Moles¹,², Pantaleo Romanelli², Federico Zara³, Pasquale Striano⁴, Saskia Biskup² and Roberto Coccurello²

1Institute of Cell Biology and Neurobiology, CNR, Via del Fosso di Fiorano, 64 00143, Roma, Italy
2Genomniasrl, Via Nerviano 31/b 20020 Lainate (MI), Italy
3Centro Diagnostico Italiano, Via Saint Bon 20, 20147, Milano, Italy
4Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, University of Genoa, “G. Gaslini” Institute, Genova, Italy
5CeGaT GmbH, Paul-Ehrlich-Str. 17, Tuebingen, Germany

Abstract

More than half of all epilepsies have some genetic basis and single gene defects in ion channels or neurotransmitter receptors are associated with some inherited forms of epilepsy. Genetic research even in the field of epilepsy disorders is increasing in term of testing platform for the investigation of sequence and structural variation. Next generation sequencing (NGS), i.e., high-throughput sequencing technologies now allow analyses that were previously prohibitive. Targeted resequencing methods by diagnostic panels enable to sequence all the genes associated with a certain disease simultaneously within a few weeks. In this review, we will discuss the overall helpfulness and convenience of simultaneous genotyping of multiple epilepsy genes by NGS in a pharmacogenetics perspective.

Keywords: Epilepsy; Genetics; Next-generation sequencing; Candidate genes

Introduction

It has been estimated that more than half of all epilepsies have some genetic basis and over the past decade important progresses have been made in the understanding of the genetic causes of many of these epilepsies. Single gene defects in ion channels or neurotransmitter receptors are associated with some inherited forms of epilepsy [1-6]. In addition, genetic discoveries in the field of infantile epilepsy syndromes have highlighted the possible different aetiologies other than channelopathies can result in epilepsy [7]. The importance of genetic testing has been heightened in clinical contexts where the identification of a specific cause may clarify the prognosis, identify the best available treatment, and define the risk of recurrence for current and future family members and avoid invasive and or prolonged diagnostic processes [8]. Moreover, genetic testing allows understanding the role of the mutation and its relationship with the phenotype, thus helping in the definition of points of action for future therapies. The lack of substantial and long-lasting relief of unprovoked seizures, regardless the introduction in the past 15 years of a wide number of second-generation antiepileptic drugs (AEDs), epitomizes the necessity of a paradigm shift including a massive effort in the clarification of certain genetic determinants of this chronic neurological disorder [9,10]. As far as pharmacological research is assimilated in the domain of the "system biology" [11], the idea of designing high selective ligands for complex multi-factorial syndromes is losing its attractiveness and clinical usability [12]. In its place, the "network pharmacology" approach (Hopkins [13]) may permit to abandon the genetic reductionism and the magic bullets philosophy, shifting our attention towards magic shotguns aimed at discovering unexpected multiple drug targets and customized pharmacotherapies [14,15].

Nowadays, the genomic era is entering in the most challenging phase, in which the identification of multiple genes involved in the pathophysiology of heterogeneous diseases requires to be intertwined with the mechanisms of action of existing as well as novel therapeutic entities. Genetic research even in the field of epilepsy disorders is increasing in term of testing platform for the investigation of sequence and structural variation. Next generation sequencing (NGS) refers to high-throughput sequencing technologies that have developed during the past years. Thanks to these technologies cloned amplified DNA templates, or single DNA molecules, are sequenced in a massively parallel way in a flow cell.

Thus, each clonal template or single molecule is "individually" sequenced and can be counted amongst the total sequences generated. The high-throughput combination of qualitative and quantitative sequence information generated has allowed analyses that were previously either not technically feasible or cost prohibitive. Targeted resequencing methods by diagnostic panels enable to sequence all the genes associated with a certain disease simultaneously within a few weeks. It is considerably less expensive than sequencing genes individually and also increases the probability to detect the genetic cause of the illness. Variant detection is based on careful and conservative mapping of the reads to the genome reference and extraction of the alignments corresponding to the targeted genes. Variants called by the primary analysis software are annotated including data on heterozygosity/homozgyosity ratio when existing; localization with respect to the gene structure; function (missense, nonsense etc) and possible involvement in disease of all the variants overlapping with a dbSNP or 1000. Moreover, the discovery of novel variants can generate new evidences to add to the panel catalog. The systematic review of all genes associated with seizure disorders is beyond the scope of this paper whereas we will discuss the overall helpfulness and convenience of simultaneous genotyping of multiple epilepsy genes by NGS in a pharmacogenetics perspective.
Epilepsy: A Complex Disease with Several Potential Therapeutic Targets

Epilepsy and pharmacogenetics

The progression in the pharmacogenetic of epilepsies opens new perspectives for the understanding of epileptogenesis and early diagnosis. In the field of drug discovery for safer, effective and tailored antiepileptic prescriptions, the term pharmacogenetic is generally applied to the investigation of the relationship between individuals’ genetic makeup and the response to a certain class of medications including toxicity and the incidence and magnitude of unwanted adverse effects [16]. Pharmacogenetics or pharmacogenomics focuses on the problem of variation in DNA and RNA, at genomic level, and impact of these changes (e.g., expression, activity, specificity of gene product) in individual variability in drug response. In this view, pharmacogenetics should help to detect patients that may benefit from a selected therapy (“magic shotguns”) characterized by lower risk of adverse reactions and possible pharmacoresistance.

Emblematically, pharmacoresistance and refractoriness to AEDs is a recurrent problem in epilepsy pharmacotherapy. Pharmacoresistance to AED treatment occurs in 25-30% of patients [17] and current mechanistic hypotheses point towards the involvement of drug transporters in the blood brain barrier such as P-glycoprotein (P-gp), whose expression is increased in brain tissue from epileptic patients, in models of brain epileptogenic and inversely associated to many AEDs in brain concentration [18,19]. Moreover, many AEDs (e.g., phenytoin, levetiracetam, lamotrigine, topiramate) are recognized high- to low- grade affinity substrates of P-gp [20-22]. In humans MDR1 (ABCB1) and MDR2 (ABCB4) genes [23] encode P-gp and exploring the genetic of P-gp overexpression in epileptic brain may assist to explore the dilemma about constitutive or developed pharmacoresistance as result of recurrent seizures or chronic AEDs treatment. Despite controversial data and poor confirmation [24, 25], a polymorphism of ABCB1 expression (C to T) at position 3435 (CC genotype) has been described in association with pharmacoresistance in epilepsy [26]. Nevertheless, analysis and further examination of different polymorphisms in other transporters, as for multidrug resistance-associated protein MRP2 (ABCC2), may provide great advancement for the improvement of efficacy of some AEDs [27, 28]. On the other hand, possible morphological alterations of the molecular site of action of AEDs may underlie the occurrence of pharmacoresistant seizures. A genetic form underlying the alterations of the target of phenytoin and carbamazepine has been described in case of polymorphism of the SCN1A gene encoding an isoform of the voltage-activated sodium channels [29, 30].

The study of individuals’ drug resistance to antiepileptic therapy or refractory seizures significantly challenges the clinical management of epilepsies. Thus, the first fundamental benefit of the pharmacogenetic approach is that it may offer a tool to recognize the consistency between epilepsy-associated genes and molecular targets of current AEDs. In this view, the assessment of eligible AEDs is “gene-driven hypothesis” and do not consider the genomic action of AEDs as major method of analysis.

Voltage- and ligand-gated ion channels

In lack of clearly detectable “structural” originof epileptogenesis, the “idiopathic generalized epilepsy” (IGE) represents the most common disease entity. Probably the most investigated epilepsy genes are those related to the syndromic entity known as channelopathies [31] in which mutations of single gene encoding voltage-gated sodium, potassium, calcium, potassium and chloride channels are increasingly recognized [32]. Thus, uncovering the genetic basis of channelopathies has strengthens the notion of epilepsy as ion channel disorder and led to develop genetic testing as clinical tool for diagnosis and treatment. Voltage-gated sodium channels (VGSCs) are critical to evoke action potential in excitable cells such as neurons. Not surprisingly, considering the key function of VGSCs in cell depolarization and propagation of action potential to another axon segment, the majority of genetic epilepsy syndromes (e.g., benign familial neonatal infantile seizures or severe myoclonic epilepsy of infancy) are described in association with sodium channels mutations [33,34].

Nevertheless, equally important is the role attributed to mutations of ligand-gated ion channel and pathogenesis of idiopathic epilepsy and in particular to those identified in nicotinic acetylcholine receptor (AChR) and GABAA receptor subunits [35,36]. For example, the role of polymorphisms and mutations in genes encoding extrasynaptic GABAA receptor and their association with human epilepsies is mirrored by the tonic inhibition provided by GABAA receptors and its importance for the efficacy of AEDs such as barbiturates, topiramate and retigabine [36-39] but also for benzodiazepine-resistant seizures [40]. The importance of ligand-gated ion channels for seizure disorders is epitomized by the clinically relevant consequences caused by mutations occurring in single subunits of nicotinic AChRs. As formerly noted [41], the association between mutation in CHRNA4, the gene encoding for the alpha 4 subunit of the nicotinic AChR, and the autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) became paradigmatic of the importance of nicotinic AChRs for the understanding of epileptogenesis.

Gene mutations, voltage- and ligand-gated ion channels and epilepsy syndromes

Prototypical targets, in this regard, are the frequent mutations recognized in genes known to encode distinct isoforms of alpha-1 (Nav1.1), alpha-2 (Nav1.2) and beta-1 sodium channels subunits (Table 1).

Missense mutations, and therefore alterations of codon nucleotide sequences and incorporation of different amino acids into channel subunits, have been identified for SCN1A (Nav1.1), SCN2A (Nav1.2) and SCN1B (subunit beta-1). These missense mutations are recognized responsible of different dominant idiopathic epilepsies and seizures termed “generalized epilepsy with febrile seizure plus” (GEFS+) [42-45]. Besides GEFS+, a high percentage of patients diagnosed for severe myoclonic epilepsy of infancy (SMEI or Dravet syndrome) show concomitant mutations in the SCN1A gene [46,47]. Less frequently Dravet syndrome has been described in association with SCN2A [48], SCN9A [49], SCN3A and SCN1B gene mutations [50,51]. Moreover, a contribution of the SCN2A gene is also recognized in the benign familial neonatal-infantile (BFNIS) and benign familial infantile seizures (BFIS) [52,53]. Mutations underlying the GEFS+ phenotype show the contribution of another key target of epileptic channelopathies. Fast synaptic inhibition is mainly mediated in the brain by the 5-subunits pentameric channels gamma-aminobutyric acid (GABA) A receptor (GABAA-R) and aberrant GABAAR-mediated signaling is largely responsible for facilitation of seizures occurrence. Indeed, the inhibitory GABAAR signaling allows chloride influx through the channel pore, thus leading to cell hyperpolarization.

Excessive inhibition may be a cause of seizures (e.g., via dishinhibition of epileptogenic network) and enhanced GABAA-R tonic inhibition of...
The heterogeneous group of monogenic and polygenic epilepsies known as idiopathic absence epilepsies (IAEs) includes all the forms represented by the idiopathic generalized epilepsies (IGEs). In the IGE group, further recognition of the childhood absence epilepsy (CAE), the juvenile absence epilepsy (JAE) as well as the juvenile myoclonic epilepsy (JME) [66]. Hence, since IGEs include a variety of syndromes and families often display more than one single phenotype, it is possible to hypothesize the presence of genes in common to different IGE subtypes. Typically, absence epilepsies are nonconvulsive epileptic seizures and genotypization (e.g., candidate gene approach, association analysis) has allowed to detect important susceptible genes of GABAAR subunits involved in these complex idiopathic epilepsies, such as: GABRA1 (α-1 subunit), GABRD (δ-3 subunit), GABRB3 (β-3 subunit), GABRG2 (γ-2 subunit) [67,68]. Mutations of GABRG2 gene have been associated with an autosomal dominant form of CAE with febrile seizures [69,70] and frameshift mutations (i.e., 1-2 nucleotides deletion or insertion with changes of downstream codons) of GABRA1 gene have been revealed in autosomal dominant JME as well as in CAE patients [71,72]. GABRB3 missense mutations in coding sequences were found associated with CAE [73] while decrease of GABAA-R current amplitude and δ subunit-mediated tonic inhibition associated with different GABRD variants and autosomal dominant JME [74,75].

IAEs have been also diagnosed in association with mutations of voltage-dependent calcium and potassium channels, such as: CACNA1H (T-type calcium channel, α1 subunit), CACNA1A (P/Q type calcium channel, α1A subunit), CACNG3 (calcium channel γ-3 subunit), CACNB2 (potassium, shaker-related subfamily, β-3 subunit), KCNQ2 (potassium channel Shal-related subfamily, member 2), KCNBD2 (Shal-related subfamily) [54]. However, autosomal-dominant epilepsy such as GEFS+ may also be associated to mutations in GABAAR-R, and in particular to the gene encoding the γ-2 subunit (GABRG2) that have been reported in febrile seizures, SMEI and GEFS+ families [35,55-57]. Notably, it has been recently shown that increasing temperature of sodium channels to block depolarized membrane potentials, thus generating a decrease in conduction that is both voltage- and frequency-dependent [61,62]. Some newer second- and third generation AEDs also show a similar primary mechanism of action, and elisecarbazepine, oxcarbazepine, lamotrigine and rufinamide are all drug of choice for partial-onset seizures and generalized tonic-clonic seizures (GTCS) but also for the control (e.g., lamotrigine, rufinamide) of Lennox-Gastaut syndrome [63,64]. Interestingly, in spite of their mechanism of action (i.e, voltage-dependent sodium channels inhibition), AEDs such as carbamazepine, phenytoin and lamotrigine can exacerbate the occurrence of myoclonic seizures in patients diagnosed for GEFS+ and SMEI syndromes [65].

### Table 1 Main Genes, Epilepsies and AEDs

| Human Gene | Identified Epilepsy syndromes | Mostly Prescribed AEDs |
|------------|------------------------------|------------------------|
| SCN1A      | Na,1.1                       | GEFS+/SMEI             |
| SCN2A      | Na,1.2                       | GEFS+/SMEI/BNFNS/Ecps  |
| SCN3A      | Na,1.3                       | SMEI                   |
| SCN1B      | sodium channel β-1 subunit   | GEFS+/SMEI             |
| SCN9A      | Na,1.7                       | STP, TPM, VA           |
| CACNA1A    | HVA - Cav2.1                 | progressive ataxia with AS |
| CACNA1G    | LVA - Cav3.1                 | IGE (CAE, JME)         |
| CACNA1H    | LVA - Cav3.2                 | IAΕ (CAE)              |
| CACNG3     | calcium channel γ-3 subunit  | AS (CAE)               |
| KCNQ2      | Kv7.2                        | BNFS                   |
| KCNQ3      | Kv7.3                        | BNFS                   |
| KCNA1      | Shaker-related subfamily, 1  | EA1m                   |
| KCNAB2     | Shaker-related subfamily, 1  | 1p36DS                 |
| KCNBD2     | Shal-related subfamily       | TLE                    |
| CACNA1H    | T-type, α1-1 subunit         | IGE/CAE                |
| CACNA1A    | P/Q type, α1-1 subunit       | IGE/CAE2/FHM/CAE       |
| CACNG3     | gamma-3 subunit              | CAE                    |
| GABRA1     | α1-1 subunit                 | JME/CAE                |
| GABRD      | delta subunit                | IGEs                   |
| GABRB3     | beta-3 subunit               | CAE                    |
| GABRG2     | GABA-R γ-2 subunit           | GEFS+/SMEI/CAE/JME     |

The occurrence of myoclonic seizures in patients diagnosed for GEFS+ and SMEI syndromes [65].
KCNA1 (potassium, shaker-related subfamily, member 1), KCNQ2 and KCNQ3 (potassium channels KQT-like subfamily, member 2 and 3, respectively) \[67,68,75,76\]. In contrast to high voltage-activated (HVA) calcium channels, low voltage-activated (LVA) T-type calcium channels are activated by small, near resting membrane potential, depolarizations. T-channels modulate calcium influx, membrane depolarization, generation of low threshold spikes and sodium-dependent action potentials and the effects of T-type channels upregulation in IGE has been supported by several animal models of absence epilepsy \[77,78\]. For instance, absence epilepsy is accompanied by 3-4 Hz spike wave discharge and the thalamocortical circuit is believed to reinforce the synchronized oscillatory activity in this circuit and maintain this pattern of discharge. Hence, LVA calcium T-channels are considered essential players in the regulation of neural pacemaker activity and synchronized neuronal oscillations of thalamocortical networks and responsible of spike wave discharge in absence epilepsy \[79,80\]. Indeed, variants in the CACNA1H gene are considered risk factors for susceptibility to IGEs pathogenesis \[81\] and different single nucleotide polymorphisms of this gene have been found associated to CAE \[82\].

Moreover, introducing these polymorphisms into human Cav3.2 cDNA was demonstrated to increase calcium influx and neural firing propensity (e.g., increased T-type channel activity) in transfected HEK-293 cells, thus supporting the idea that susceptibility of CACNA1H gene may increases liability to seizures and CAE-like polygenic disorders \[83\].

The CACNA1A gene encodes the alfa-1A subunit of HVA calcium channels, which belongs to Cav2 family that includes the splice isoform to Cav2.1 subfamily (P/Q type calcium channel) \[84\]. The alfa-1A subunit is mostly expressed in the neuronal tissue at presynaptic nerve terminals and the functional activity of P/Q type channels appears linked to activity-evoked excitatory neurotransmitter release and signaling integration \[85,86\]. As noted above, sychronic and bilateral spike wave discharges involving the thalamocortical network are a hallmark for the diagnosis of IGEs. In this regard, different mouse lines and spontaneously occurring homozygous mutants (e.g., tottering and rocker mice) harbouring mutations in the genes coding for brain Cav2.1 channels have been exploited as suitable models for human absence epilepsy reproducing both neural hyperexcitability and bilateral spike wave discharges \[87,88\]. Notably, mutations in P/Q-type calcium channels and in particular CACNA1A missense mutations are recognized causes of a wide spectrum of neurological diseases, such as episodic ataxia type 2 (EA2) and familial hemiplegic migraine (FHM) \[89-92\] with co-occurrence of childhood epilepsy \[93\]. Interestingly, a CAE-like syndrome has been hypothesized to be associated with a stop mutation in the gene (CACNA1A) encoding P/Q-type calcium channel α-1A subunit, with a loss of Cav2.1 function and decrease of calcium current in a complex case of mixed cerebellar ataxia and absence seizures phenotype \[94\].

A benign familial neonatal seizure (BFNS) is an autosomal dominant epilepsy syndrome characterized by focal and unprovoked tonic-clonic seizures. It is now recognized that mutations in the genes encoding the potassium channel KQT-like subfamily member 2 (Kv7.2) and member 3 (Kv7.3) are accountable for the BFNS pathophysiology. Indeed, the co-segregation of both chromosome 20q13.3 and 8q24 deletions and BFNS phenotype, has allowed the characterization of missense mutations of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) as candidate genes of primary importance in BNFS etiology \[95-102\].

KCNQ2 and KCNQ3 mutations or duplications have been described in association to BNFS clinical features \[103,104\]. As members of the potassium channel of KCNQ gene family, KCNQ2 and KCNQ3 subunits can co-assemble and form heteromultimeric or heterotetramers channels that mediate neuronal muscarinic-regulated current (M-current or M-type K+ channel) \[105,106\]. The M-current is active near the threshold for action potential initiation and slowly originate when neurons depolarizes, thus enabling membrane repolarization and re-establishing of resting potential and firing ceasing. The M-current is therefore a low-threshold noninactivating potassium conductance that plays a key role in neuronal excitability and responsiveness to synaptic input and both KCNQ2 and KCNQ3 subunits have been shown to contribute to this current \[107,108\]. From a functional point of view, KCNQ2 and KCNQ3 mutations and consequent loss of heteromeric KCNQ2/KCNQ3-channel function are translated in a significant decrease of the Kv7.2 and Kv7.3 channels that produce facilitation of membrane depolarization, neuronal hyperexcitability and seizure susceptibility in BFNC \[109\]. Hence, since the suppression of M-current evokes membrane depolarization and increase of neural input resistance, muscarinic cholinergic agonists possess an epileptogenic potential that is conveniently explored in epilepsy models \[109,110\]. Interestingly, a recent study has described eight novel KCNQ2 mutations in families with BFNS that include missense start codon mutations, frameshift mutation and truncation, and putative splice sites and missense mutations in the C-terminal region of KCNQ2 \[110\]. In particular, this study has provided evidence that C-terminal missense mutation can change the conformation of KCNQ2 C-terminal domain, thus suppressing the ability to bind to calcium protein calmodulin (CaM) with a possible decrease of channel opening and impairment of M-currents. Hence, according to these results, CaM is potentially involved in the BFNS pathogenesis. KCNA1 (Kv1.1) is another interesting epilepsy-susceptibility gene, a member (1) of shaker-related subfamily that appears mutated in episodic ataxia type 1 (EA1 with myokymia) \[111\], a rare autosomal dominant disorder frequently associated with an increased incidence of epilepsy \[112\].

**Novel Therapeutic Options for Epilepsy Management and Gene Targets**

Drug discovery for novel anticonvulsants (AEDs) may potentially greatly benefit from the identification of susceptible genes involved in epilepsy pathophysiology. Recent progress in the identification of human genetic mutations has been exploited to develop animal models able to recapitulate many phenotypic characteristics of channel dysfunction in different epilepsy syndromes. For instance, mice carrying mutations in the gene encoding voltage-gated sodium channel Nav1.1 (SCN1A) show reduced sodium currents in GABAergic inhibitory interneurons and replicate hyperexcitability and spontaneous seizures observed in human SMEI \[113\]. A Scn1b knockout mouse for the C121W mutation of the beta-1 sodium channel subunit reproduced the heterozygous SCN1B mutation found in patients with GEFS+, and identified in beta-1 subunit modulation of excitability of the membrane of axon initial segments of pyramidal neurons a possible determinant of heat-sensitive seizures \[114\]. A different model of GEFS+ was engineered to harbour the GABRG2 (R43Q) mutation and mimic the phenotype observed in patients suffering from GEFS+ or CAE \[115\]. Mouse models carrying the missense point mutations in Kcnq2 and Kcnq3 described in human BFNC exhibit spontaneous tonic-clonic seizures or reduced threshold to experimentally evoked seizures as well as enhanced liability to seizures later in life \[116\].

Citation: Moles A, Romanelli P, Zara F, Striano P, Biskup S, et al. (2014) Targeted Resequencing of Epilepsy Genes: A Pharmaco-Therapeutic Perspective. Int J Neurorehabilitation 1: 116. doi:10.4172/2376-0281.1000116
Up to now, the availability of a variety of mouse mutant mimicking human epilepsy has been inadequately implemented in antiepileptic drug discovery. It is, however, widely accepted that somneother and newer AEDs such as carbamazepine, eslicarbazepine, lacosamide, gabapentin, phenytoin, topiramate and valproate block or slowly inactivate (e.g., eslicarbazepine) voltage-gated sodium or calcium channels, thus inhibiting repetitive and sustained neuronal firing. Nevertheless, AEDs share multiple mechanisms of action and there are novel recognized molecular targets both for traditional and emerging AEDs that encourage the identification of gene mutations in epilepsies. Despite the initial underestimation of the role of voltage-gated potassium channels in the mechanism of action of several AEDs, it is now accepted that this large family of ion channels is a target of different AEDs. Phenytoin can also inhibit A-type potassium channel [117], topiramate facilitates membrane hyperpolarization by acting on potassium conductance [118] and lamotrigine can block hippocampal A-type potassium channels [119]. In parallel, lamotrigine has also been shown to reduce hippocampal glutamate-mediated transmission by inhibiting postsynaptic AMPA receptors [120].

Other second-generation antiepileptics, such as the piracetam-related levetiracetam and the carbamazepine-related oxcarbazepine, decrease delayed rectifier potassium currents and block sustained repetitive firing [121,122]. Notably, retigabine is a newly discovered and recently marketed AED that show an interesting mechanism of action. Indeed, retigabine may be considered a prototype of a new class of antiepileptic compounds targeting Kv7.x potassium channels (KCQN) [123]. Although retigabine can enhance GABAergic transmission and GABA-induced chloride currents, it mainly acts as enhancer of the neuronal M-type potassium current mediated by Kv7.2-Kv7.3 channels [124]. Probably by destabilization of channels closed conformation and enhancement of open channels probability, retigabine reduces and accelerates the threshold for activation of M-current, thus increasing the current amplitude at negative potentials [124-126].

A different target for different novel AEDs is represented by the synaptic vesicle protein 2 isoform A (SV2A), a regulatory membrane glycoprotein found on synaptic vesicles of neurons and endocrine cells that contributes to membrane fusion processes underlying calcium-regulated neurotransmitter secretion. In the brain, SV2A is the binding site for the newly developed AED levetiracetam and its high-affinity structural analogue brivaracetam that also inhibits neuronal voltage-gated sodium channels [127].

Although the mechanism by which levetiracetam prevents seizures is not yet clarified, it is known that SV2a is double knockout mice exhibit sustained increase in calcium-dependent synaptic transmission and spontaneous seizures compatible with a state of heightened epileptogenesis [128]. Sv2a dysfunction may therefore lead to calcium accumulation, excitatory transmission facilitation and attenuation of inhibition and levetiracetam treatment has been shown effective in patients with refractory epilepsy [129] as well as in management of human pain [130,131]. Hence, the identification of SV2A as binding site for levetiracetam and brivaracetam [127,132] opens new avenues in the discovery of novel molecular targets for seizures treatment.

Similarly, human genetic analysis has helped to disclose another not obvious potential novel molecular target for AEDs in the gene (SLC2A1) encoding the glucose transporter GLUT1, which is the main transporter for D-glucose across the blood brain barrier. De novo or inherited heterozygous mutations in the GLUT1/SLC2A1 gene give rise to cerebral energy failure and a clinical condition known as GLUT1-deficiency syndrome (GLUT1-DS). Within the different phenotypes described to occur in GLUT1-DS, the familial paroxysmal exertion-induced dyskinesia (PED) can result associated to epileptic seizures.

Indeed, the hypothesis of shared genetic determinants for paroxysmal dyskinesia (PD) and epilepsy appears corroborated by the co-occurrence of PED and epileptic seizures (i.e., generalized tonic-clonic or absences) in patients carrying mutations in SLC2A1 gene [105]. This study identified a region on chromosome 1p35–p31 including SLC2A1, with heterozygous missense and frameshift mutations segregating in families with a similar phenotype in which some patients positively responded to ketogenic diet (KD) treatment [133]. Hence, according to this report, the concomitant manifestation of PED and epilepsy appears attributable to autosomal dominant heterozygous SLC2A1 mutations, which have also been found in a sub-cohort of patients with early-onset absence epilepsy diagnosis and without PED [134]. In addition, a large European study on revealed that GLUT1 defects are a rare cause of familial IGEs. In particular, SLC2A1 screening should be considered in patients featuring absence epilepsies with onset from early childhood to adult life. This diagnosis may have important implications for treatment and genetic counseling [135]. In fact, in many cases, these individuals can be responsive to KD treatment that is the object of renewed attention for the management of intractable epilepsies in child as well as in adult patients [136,137]. When glucose transport is defective, as in GLUT1 deficiency, the KD allows easily deliveringof ketone bodies and energy supplement to the brain. However, although ketone bodies possess anticonvulsant properties, the mechanisms underlying the clinical efficacy of sustained ketosis remain elusive [138]. KD is based on the ingestion of very low-carbohydrate diet and one hypothesis of KD efficacy predicts that KD-induced seizure control might depend on the inhibition of glycolysis and carbohydrate metabolism. In support of this view, the administration of the glycolysis inhibitor 2-deoxy-D-glucose (2DG) is reported to induce both in vitro and in vivo anticonvulsant actions by reducing pharmacologically-induced interictal epileptiform burstings in hippocampal slices as well as 6Hz stimulation-evoked seizures in mice and the progression of epileptogenesis in kindling model of TLE in rats [139,140]. Despite the large number of availableAEDs, several epilepsy syndromes are medically intractable and TLE shows one of the worst prognoses. In this context, the further investigation of 2DG inhibitors is one more promising path worth pursuing. Recently confirmed in a high number of familial cases examined [135,141], the phenotypic spectrum (e.g., IGEs) associated to SLC2A1 mutations highlights the importance of GLUT1 deficiency as monogenic cause of absence epilepsies and suggests new potential strategies of intervention.

Targeted Resequencing of Epilepsy Genes: From Genomes to Diagnostic Panels of Genes

Using sequencing machines available today, high-throughput next generation sequencing permits the simultaneous sequencing of several billion basespairs within one week, i.e. the complete haploid human genome (3 billion basespairs in total). Because of higher accuracy and data quality and for reasons of better understanding of variation there is an advantage to focus on the coding regions of the human genome. The human exome, the totality of all coding regions in the genome reduces the amount of basespairs to be analyzed to 30 million. Sequencing an exome is useful if there are strong indications for a genetic disease, all known genes associated with epilepsy have been ruled out and this approach is applied and evaluated by experts in the particular field within the scope of a research project. In contrast, a diagnostic panel for epilepsy is the targeted simultaneous screening of a list of known genes that have already been described as the cause of
seizures. A diagnostic panel in general clearly differs from the purely scientific and explorative approach of exome sequencing. A diagnostic panel analyses only the genes whose connection with the disease have been established (Table 1). As new genes are described almost every week the list has to be updated on a regular basis. Based on the gene identifier and the respective genomic sequences complementary RNA baits are designed to capture the regions of interest.

On array and in solution hybridization technologies are used in these cases allowing massive parallel hybridization and capture of relevant sequences. Target amplification is another option and can be used as standalone method or in combination with hybridization based methods in order to cover problematic repetitive or GC rich regions. After enrichment for the defined target that can be up to several 10 megabases in size, the DNA fragments are amplified on beads and subsequently massively sequenced. Before a diagnostic panel can be offered for diagnostic purposes it must be validated. Within the framework of such validation patients whose variations are already known are “post”-sequenced on the panel. This requires that 100% of the known variations are found by the panel sequencing approach. Furthermore, the enrichment of the genomic regions must be efficient, specific and reproducible. Epilepsies are very suitable for a targeted next generation sequencing approach as several large genes and gene families have been described as cause and genetic diagnostics in cases was not only very time-consuming, but was either inefficient or not performed because of high costs. In comparison to whole exome sequencing, the decreased number of genes within the panel allows a significant increase in coverage on target sequences. This helps to reliably detect mutations, to screen tens of patients in parallel and most important to prevent detection, validation and interpretation of variants in genes not known to account for a patient’s phenotype.

Lemke and co-authors [142] put together a panel of genes comprising the most relevant epilepsy genes and epilepsy phenotypes (265 genes in total). A pilot cohort of 33 index patients representing both isolated and familial cases with either concisely epilepsy phenotypes was considered. The panel covers exonic regions as well as exon-intron boundaries of the vast majority of all currently well-known epilepsy genes. To facilitate further analysis the 265 genes were subdivided into subpanels according to clinically relevant groups of epilepsy phenotypes (Table 1). Using a customized target in solution enrichment followed by next generation sequencing a screening for mutations in the 265 candidate genes (875.678 base pairs in total) was performed. The detected variants were then evaluated with respect to the individual phenotype and all putatively causative mutations were validated by conventional Sanger sequencing. To determine the impact of novel variants segregation analysis in families was applied if possible. In a preliminary study [115], this diagnostic epilepsy panel identified gene mutations in 15 out of 33 (45%) patients. A known KCNQ3 mutation was detected in a patient with rolandic epilepsy and a SCN1A de novo mutation (R393H) was identified in a patient with Dravet syndrome.

Notably, in a handful of cases mutations were found in genes that are not routinely sequenced. For instance, a homozygous missense mutation was identified in the KCTD7 gene in some patients with progressive myoclonic epilepsy [143]. Additionally, pathogenic mutations were found in STXBP1, ARHGEF9, TIP1, MFSD8, KCNJ10, FLNA, SCN1A, and SCN2A [142]. Most interestingly and most intriguing, known pathogenic SCN1A mutations were detected by next generation sequencing in two patients with classic Dravet syndrome that have been tested negative by conventional Sanger sequencing in accredited laboratories. After knowledge of these mutations the variants were confirmed with subsequent Sanger sequencing in both cases. A precise delineation of a patient’s epilepsy phenotype can often be difficult due to a significant phenotypic overlap shared by many seizure disorders. Using massive parallel sequencing the detection rate of genetic aberrations does no longer depend on the prerequisite of a precise clinical diagnosis and consecutive prediction of putatively casual genes. It seems rather sufficient to categorize the patient’s epilepsy in a rough group of phenotypes (e.g., according to a subpanel) and primarily screen the respective genes. Compared to the classic time, effort and cost consuming stepwise Sanger sequencing screening of disease specific panels seems more than just a straightforward and efficient alternative. The significantly higher coverage of targeted genes compared to whole exome sequencing within the epilepsy panel considerably increases the probability to detect relevant variations within the genes of interest.

Conclusions

The ultimate goal of personalized medicine is to develop individualized treatments tailored to every patient. Variants in the genome have a demonstrated impact in different aspects of drug therapy: drug effect on receptors and signaling pathways, and drug dose-related adverse reactions drug transportation, drug metabolism. Disease specific NGS panel of genes represents a powerful tool for uncovering underlying genetic defects in patients suffering from various seizure disorders and contributes to genotype-phenotype correlations of rare epilepsy syndromes and the choice of the best therapy.

References

1. Weber YG, Lerche H (2008) Genetic mechanisms in idiopathic epilepsies. Dev Med Child Neurol 50: 645-654.
2. Poduri A, Lowenstein D (2011) Epilepsy genetics—past, present, and future. Curr Opin Genet Dev 21: 325-332.
3. Mulley JC, Scheffer IE, Petrov S, Berkovic SF (2003) Channelopathies as a genetic cause of epilepsy. Curr Opin Neurol 16: 171-176.
4. Mouldard B, Picard F, le Héillard S, Aгуlhon C, Weiland S, et al. (2001) Ion channel variation causes epilepsy. Brain Res Rev 36: 275-284.
5. Striano P, Zara F (2011) Genetic epilepsies. Eur J Paediatr Neurol 15: 88-89.
6. Nicita F, Di Liso P, Danti FR, Papetti L, Ursitti F, et al. (2012) The genetics of monogenic idiopathic epilepsies and epileptic encephalopathies. Seizure 21:3-11.
7. Deprez L, Jansen A, De Jonghe P (2009) Genetics of epilepsy syndromes starting in the first year of life. Neurology 72: 273-281.
8. Pal DK, Pong AW, Chung WK (2010) Genetic evaluation and counseling for epilepsy. Nat Rev Neurol 6: 445-453.
9. Perucca E, French J, Bialer M (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6: 793-804.
10. Shorvon SD (2009) Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia 50:93-130.
11. Ho RL, Lieu CA (2008) Systems biology: an evolving approach in drug discovery and development. Drugs R D 9: 203-216.
12. Schrattenholz A, Groebe K, Sosnik V (2010) Systems biology approaches and tools for analysis of interactomes and multi-targeted drugs. Methods Mol Biol 662: 239-58.
13. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
14. Erickson RP (1998) From “magic bullet” to “specifically engineered shotgun loads”: the new genetics and the need for individualized pharmacotherapy. Bioessays 20: 683-685.
15. Mencher SK, Wang LG (2005) Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 5: 3.
16. Anderson GD (2008) Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit 30: 173-180.

17. Wiebe S, Jette N (2012) Pharmacoresistance and the role of surgery in difficult to treat epilepsy. Nat Rev Neurol 8: 669-677.

18. Löschner W, Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6: 591-602.

19. Schmidt D, Löschner W (2009) New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr 9: 47-52.

20. Kwan P, Brodie MJ (2005) Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsy 46: 224-235.

21. Löschner W, Potschka H (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76.

22. Moerman L, Wyffels L, Slaets D, Raedt R, Boon P, et al. (2011) Antiepileptic drugs modulate P-glycoproteins in the brain: a mouse study with (11) C-desmethylloperamide. Epilepsy Res 94: 15-25.

23. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, et al. (2010) Pharmacogenomics of membrane transporters: an update on current approaches. Mol Biotechnol 44: 152-167.

24. Leschziner G, Jorgensen AL, Andrew T, et al. Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol2006; 5: 668-676.

25. Nummohamed L, Garcia-Boumnissen F, Buono RJ, et al. Predisposition to epilepsy—does the ABCB1 gene play a role?Epilepsia2010; 51: 1882–1885.

26. Siddiqi A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, et al (2003)Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348:1442-1448.

27. Potschka H, Fedrowitz W, Löschner W (2003) Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306: 120-131.

28. Yi JH, Cho YJ, Kim WJ, Lee MG, Lee JH (2013) Genetic Variations of ABC2 Gene Associated with Adverse Drug Reactions to Valproic Acid in Korean Epileptic Patients. Genomics Inform 11: 254-262.

29. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom Dev 31: 758-762.

30. Abe T, Seo T, Ishitu T, Nakagawa T, Hori M, Nakagawa K (2008) Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol55:375-378.

31. Heron SE, Scheffer IE, Berkovic SF, Dibbens LM, Mulley JC (2007) Channelopathies in idiopathic epilepsy. Neurotherapeutics 4:295-304.

32. Scheffer IE, Berkovic SF The genetics of human epilepsy. Trends Pharmacological Science 24:428-433.

33. Meisler MH, O’Brien JE, Shanker LM (2010) Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. J Physiol 588: 1841-1848.

34. Oliva M, Berkovic SF, Petrou S (2012) Sodium channels and the neurobiology of epilepsy. Epilepsia 53: 1849-1859.

35. Baulac S, Huberfeld G, Gourfinkel-An I, Mitropoulos G, Beranger A, et al. (2001) First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nature Genetics 28:46-48.

36. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA et al. (1995) A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nature Genetics11:201-203.

37. Dibbens LM, Feng HJ, Richards MC, Harkin LA, Hodgson BL, et al. (2004) GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies. Hum Mol Genet 13: 1315-1319.

38. Eugène E, Depienne C, Baulac S, Baulac M, Fritschy JM, et al. (2007) GABA(A) receptor gamma 2 subunit mutations linked to human epileptic syndromes differentially affect phasic and tonic inhibition. J Neurosci 27: 14108-14116.

39. Greenfield LJ Jr (2013) Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure 22:589-600.

40. Deeb TZ, Maguire J, Moss SJ (2012) Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures. Epilepsia 53:79-88.

41. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, et al. (1995) A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 21: 201-203.

42. Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, et al. (2000) Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 24: 343-345.

43. Escayg A, Heils A, MacDonald BT, Haug K, Sander T, et al. (2001) A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus and prevalence of variants in patients with epilepsy. American Journal of Human Genetics68:866-873.

44. Sugawara T, Tsurubuchi Y, Agarwala KL, Ito M, Fukurna G, et al. (2001) A missense mutation of the N-ar channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proceedings of the National Academy of Sciences USA 108:6384-6389.

45. Wallace RH, Wang DW, Singh R, Scheffer IE, et al. (1998) Febrile seizures and generalized epilepsy associated with a mutation in the Na-channel beta1 subunit gene SCN1B. Nature Genetics 19:366-370.

46. Marini C, Scheffer IE, Nabibut R, Mei D, Cox K, et al. (2009) SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis. Epilepsia 50: 1670-1677.

47. Claes L, Ceulemans B, Audentert N, Smets K, Lüftenegger M, et al. (2003) De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy. Human Mutation 21:615-621.

48. Shi X, Yasumoto S, Nakagawa E, Fukasawa T, Uchiya S, et al. (2009) Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome. Brain Dev 31: 758-762.

49. Singh NA, Pappas C, Dahle EJ, Claes LR, Pruess TH, et al. (2009) A role of SCN9A in human epilepsy, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet 5: e1000649.

50. Vecchi M, Cassina M, Casarin A, Rigon C, Drigo P, et al. (2011) Infantile epilepsy associated with mosaic 2q24 duplication including SCN2A and SCN3A. Seizure20:813-816.

51. Patino GA, Claes LR, Lopez-Santiago LF, Slat EA, Dondelt RS, et al. (2009) A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci 29: 10764-10778.

52. Hertenius E, Heron SE, Grinton BE, Keay D, Scheffer IE, et al. (2007) SCN2A mutations and benign familial neonatal-infantile seizures: the phenotypic spectrum. Epilepsia 48: 1138-1142.

53. Striano P, Bordo L, Lispi ML, Specchio N, Minetti C, et al. (2006) A novel SCN1A mutation in family with benign familial infantile epilepsy. Epilepsia 47: 218-220.

54. Mann EO, Mody (2008) The multifaceted role of inhibition in epilepsy: seizuresgenesis through excessive GABAergic inhibition in autosomal dominant nocturnal frontal lobe epilepsy. Current Opinion Neurology 21:155-160.

55. Harkin LA, Bowser DN, Dibbens LM, Singh R, Phillips F, et al. (2002) Truncation of the GABA(A)-receptor gamma2a subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet 70: 530-536.

56. Macdonald RL, Kang QJ, Galagher MJ (2010) Mutations in GABAB Aceptor subunits associated with genetic epilepsies. Journal of Physiology 588:1861-1869.

57. Shi X, Huang MC, Ishii A, Yoshida S, Okada M, et al. (2010) Multipathological analysis of GABRG2 in a Japanese cohort with childhood epilepsies. Journal of Human Genetics55:375-378.

58. Bouthour W, Leroy F, Emmanuelli C, Carnaud M, Dahan M, et al. (2012) A human mutation in Gabrg2 associated with generalized epilepsy alters the membrane dynamics of GABAB receptors. Cereb Cortex 22: 1542-1553.

59. Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, et al. (2006) Reduced sodium current in GABAAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9: 1142-1149.
60. Martin MS, Dutt K, Papale LA, Dubé CM, Dutton SB, et al. (2010) Altered function of the SCN1A voltage-gated sodium channel leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities. J Biol Chem 285: 9823-9834.

61. Yafi Y, Selzter ME, Pincus JH (1986) Phenyltoin: mechanisms of its anticonvulsant action. Annals of Neurology 20: 171-184.

62. Rogawski MA, Löschner W (2004) The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience 5: 553-564.

63. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C (2008) Rufinamide for generalised seizures associated with Lennox-Gastaut syndrome. Neurology 70: 1950-1958.

64. L. J. Stephen LJ, Brodie MJ (2011) Pharmacotherapy of epilepsy: newly approved and development agents. CNS Drugs 25: 89-107.

65. Striano P, Striano S, Minetti C, Zara F (2008) Refractory, life-threatening status epilepticus in a 3-year-old girl. Lancet Neurology 7: 275-280.

66. P. Jallon P, Labort P (2005) Epidemiology of idiopathic generalized epilepsies. Epilepsia 46: 10-14.

67. Gardiner G (2005) Genetics of idiopathic generalized epilepsies. Epilepsia 46 Suppl 9: 15-20.

68. Macdonald RL, Kang JQ, Gallagher MJ, Feng HJ (2006) GABAA receptor mutations and epilepsy. Adv Pharmacol 54: 147-169.

69. Wallace RH, Marini C, Harkin LA, Bowser DN, et al. (2001) Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet 28: 49-52.

70. Audenaert D, Schwartz E, Claes KG, Claes L, Deprez L, et al. (2006) A novel GABRG2 mutation associated with febrile seizures. Neurology 67: 687-690.

71. Cossette P, Liu L, Brisebois K, Dong H, Lortie A, et al. (2002) Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet 31: 184-189.

72. Maljevic S, Krapf K, Coblanjsch J, Tilgen N, Beyer S, et al. (2006) A mutation in the GABA(A) receptor alpha1-subunit is associated with absence epilepsy. Ann Neurol 59: 983-987.

73. Tanaka M, Olsen RW, Medina MT, Schwartz E, Nonso ME, et al. (2008) Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy. Am J Hum Genet 82: 1249-1261.

74. Wallace RH, Marini C, Peterson S, Harkin LA, Bowser DN, et al. (2001) Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet 28: 49-52.

75. Lou Y, Wang X (2009) Genes associated with idiopathic epilepsies: a current overview. Neurology Research 31: 135-143.

76. Lerche H, Weber YG, Jurkat-Rott K, Lehmann-Horn F (2005) Ion channel defects in idiopathic epilepsy. Curr Pharm Des 11: 2737-2752.

77. Taylor EM, Solórzano G, Depaulis A, Perez-Reyes E, Bayliss DA (2000) Low-voltage-activated calcium channel subunit expression in a genetic model of absence epilepsy in the rat. Brain Research Molecular Brain Research 75: 159-165.

78. Broicher T, Kanyshkova T, Meuth P, Pape HC, Buddle T (2008) Correlation of T-channel coding gene expression, IT, and the low threshold Ca2+ spike in the thalamus of a rat model of absence epilepsy. Mol Cell Neurosci 39: 384-399.

79. Perez-Reyes E (2003) Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 83: 117-161.

80. Porcello DM, Smith SD, J. R. Huguenard Jr. (2003) Actions of U-92032, a T-type calcium channel blocker, on intrathalamic rhythms. Journal of Neurophysiology 89: 177-185.

81. Khosravani H, Biaden C, Parker DB, Snutch TP, McRory JE, et al. (2005) Effects of Cav3.2 calcium mutations linked to idiopathic generalized epilepsy. Ann Neurol 57: 745-749.

82. Chen Y, Lu J, Pan H, Zhang Y, Wu H, et al. (2003) Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 54: 239-243.

83. Vlko I, Chen Y, Arias JM, Shen Y, Wu XR, et al. (2005) Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of CACNA1H, a T-type calcium channel. Journal of Neuroscience 25, no. 19, pp. 4844-4855.

84. Bourinet E, Soong TW, Sutton K, Slaymaker S, Mathews E, et al. (1999) Splicing of alpha 1A subunit gene generates phenotypic variants of P- and Q-type calcium channels. Nat Neurosci 2: 407-415.

85. Trimmer JS, Rhodes KJ (2004) Localization of voltage-gated ion channels in mammalian brain. Annu Rev Physiol 66: 477-519.

86. Leenders AG, van den Maagdenberg AM, Lopes da Silva FH, Sheng ZH, Molenaar PC (2002) Neurotransmitter release from toning mice nerve terminals with reduced expression of mutated P- and Q-type Ca2+-channels. European Journal of Neuroscience 15:13-18.

87. Fletcher CF, Lutz CM, O'Sullivan TN, Shaughnessy JD Jr, Hawkes R, et al. (1996) Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 87: 607-615.

88. Pietrobon D (2002) Calcium channels and channelopathies of the central nervous system. Mol Neurobiol 25: 31-50.

89. Ophoff RA, Terwindt GM, Vergouw MN, van Eijk R, Oefner PJ, et al. (1996) Familial hemiplegic migraine and episodic ataxia type 2 are caused by mutations in the CACNA1A gene. Cell 84: 543-552.

90. Scoogkan KA, Chandra T, Nelson R, Hahn AF, Bulman DE (2001) Identification of two novel mutations in the CACNA1A gene responsible for episodic ataxia type 2. J Med Genet 38: 249-253.

91. Denier C, Ducros A, Durr A, Eymard B, Chassande B, et al. (2001) Missense CACNA1A mutation causing episodic ataxia type 2. Arch Neurol 58: 292-295.

92. Guida S, Trettel F, Pagnutti S, Mantuano E, Tottene A, et al. (2001) Complete loss of P/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2. American Journal of Human Genetics 68:759-764.

93. Kors EE, Melberg A, Vanmolkot KR, Kumlien E, Haan J, et al. (2004) Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new CACNA1A mutation. Neurology: 63:1136-1137.

94. Jouveneau A, Unsworth LH, Spauschus A, Ramesh V, Zuberi SM, et al. (2001) Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet 358:801-887.

95. Imbrie P, Joffre SL, Unsworth LH, Davies NP, Herd C, et al. (2004) Dysfunction of the brain calcium channel Cav2.1 in absence epilepsy and episodic ataxia. Brain 127: 2662-2692.

96. Rajakulendran S, Graves TD, Labrum RW, Kotzadimitriou D, Unsworth L, et al. (2010) Genetic and functional characterization of the P/Q calcium channel in episodic ataxia type 1. J Physiol 588: 1905-1913.

97. Everett KV, Choiza B, Aicardi J, Aschauer H, Brouwer O, et al. (2007) Linkage and association analysis of CACNG3 in childhood absence epilepsy. European Journal of Human Genetics 15:463-472.

98. Singh B, Ogwara I, Kaneda M, Tokonami N, Mazaki E, et al. (2006) A Kv4.2 truncation mutation in a patient with temporal lobe epilepsy. Neurobiol Dis 24: 245-253.

99. Jerng HH, Pfaffinger PJ, Covarrubias M (2004) Molecular physiology and modulation of somatodendritic A-type potassium channels. Mol Cell Neurosci 27: 343-369.

100. Heilisledt HA, Burgess DL, Anderson AE, Chedrawi A, Tharp B, et al. (2001) Loss of the potassium channel beta-subunit gene, KCNAB2, is associated with epilepsy in patients with 1p36 deletion syndrome. Epilepsia 42: 1103-1111.

101. Singh NA, Charlier C, Staufder D, DuPont BR, Leach RJ, et al. (1998) A novel potassium channel beta-subunit gene, KCNAB2, is mutated in an inherited epilepsy of newborns. Nat Genet 18: 25-29.

102. Charlier C, Singh NA, Ryan SG, Lewis TB, Rees BE et al. (1998) A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nature Genetics 18:53-55.

103. Hunter J, Maljevic S, Shankar A, Siegel A, Weissman B, et al. (2006) Subthreshold changes of voltage-dependent activation of the K(V)7.2 channel in neonatal epilepsy. Neurobiol Dis 24: 194-201.
105. Soldovieri MV, Cillo MR, Miceli F, Bellini G, Miraglia del Giudice E, et al. (2007) Atypical gating of M-type potassium channels conferred by mutations in uncharged residues in the S4 region of KCNQ2 causing benign familial neonatal convulsions. Journal of Neuroscience 27:4919-4928.

106. Marrion NV (1997) Control of M-current. Annual Review Physiology 59:483-504.

107. Biwernt C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, et al. (1998) A potassium channel mutation in neonatal human epilepsy. Science 279:430-436.

108. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, et al. (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282:1890-1893.

109. Schroeder BC, Kubisch C, Stein V, Jentsch TJ (1998) Moderate loss of function of cyclic-AMPmodulated KCNQ2/KCNQ3 K+ channels causes epilepsy. Nature 396:687-690.

110. Turski L, Ikonomidou C, Turski WA, Bortolotto ZA, Cavalheiro EA (1989) Review: cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: a novel experimental model of intractable epilepsy. Synapse 3:154-171.

111. Richards MC, Heron SE, Spendlove HE, Scheffer IE, Grinton B, et al. (2004) Novel mutations in the KCNQ2 gene link epilepsy to a dysfunction of the KCNQ2-calmudin interaction. Journal of Medicine Genetics 41:e35.

112. Browne DL, Gancher ST, Nutt JG, Brunert ET, Smith EA, et al. (1994) Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNQ1. Nat Genet 8:135-140.

113. Tomkinson SE, Tan SV, Kullmann DM, Griggs RC, Burke D, et al. (2010) Nerve excitability studies characterize Kv1.1 fast potassium channel dysfunction in patients with episodic ataxia type 1. Brain 133:3530-3540.

114. Yu FH, Mantegazza R, Westenbroek RE, Robbins CA, Kalume F, et al. (2006) Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9:1142-1149.

115. Wimmer VC, Reid CA, Mitchell S, Richards KL, Scaf BB, et al. (2010) Axon initial segment dysfunction in a mouse model of genetic epilepsy with febrile seizures plus. Journal of Clinical Investigation 120:2691-2671.

116. Tan HO, Reid CA, Single FN, Davies PJ, Chiu C, et al. (2007) Reduced cortical inhibition in a mouse model of familial childhood absence epilepsy. Proc Natl Acad Sci U S A 104:17536-17541.

117. Singh NA, Otto JF, Dahle EJ, Pappas C, Leslie JD, et al. Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization. Journal of Physiology 586:3405-3423.

118. Pisciotto M, Prestipino G (2002) Anticonvulsant phenytoin affects voltage-dependent potassium currents in cerebellar granule cells. Brain Research 941:53-60.

119. Herrero AI, Del Olmo N, González-Escalada JR, Solís JM (2002) Two potassium channel gene, KCNA1. Brain 125:1683-1691.

120. Browne DL, Gancher ST, Nutt JG, Brunert ET, Smith EA, et al. (1994) Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNQ1. Nat Genet 8:135-140.

121. Mullen SA, Suls A, De Jonghe P, Berkovic SF, Scheffer IE (2010) Early-onset absence epilepsy caused by mutations inthe glucose transporter GLUT1. Annals of Neurology 66:415-419.

122. Striano P, Weber YG, Toliat MR, Schubert J, Leeu C, et al. (2012) GLUT1 mutations are a rarecause of familial idiopathic generalized epilepsy. Neurology 78:557-562.

123. Kelley SA, Hartman AL (2011) Metabolic treatments for intractable epilepsy. Semin Pediatr Neurol 18:179-185.

124. Nam SH, Lee BL, Lee CG, Yu HJ, Joo EY, et al. (2011) The role of ketogenic diet in the treatment of refractorystatus epilepticus. Epilepsia 52:181-184.

125. Stafstrom CE, Bough KJ (2003) The ketogenic diet for the treatment of epilepsy: a challenge for nutritional neuroscientists. Nutr Neurosci 6:67-79.

126. Madeja M, Margineanu DG, Gorji A, Steig E, Boerrigter P, et al. (2003) Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic action of a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsantproperties. European Journal of Pharmacology 646:36-44.

127. Soldovieri MV, Cillo MR, Miceli F, Bellini G, Miraglia del Giudice E, et al. (2007) Atypical gating of M-type potassium channels conferred by mutations in uncharged residues in the S4 region of KCNQ2 causing benign familial neonatal convulsions. Journal of Neuroscience 27:4919-4928.

128. Lange W, Geissendörfer J, Schenzer A, Grötzinger J, Seebohm G, et al. (2009) Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol 75:272-280.

129. Lynch BA, Lambeng N, Nocka K, Kensei-Hammes P, Bajalihet SM, et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101:9861-9866.

130. Janz R, Goda Y, Geppert M, Missler M, Südhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24:1003-1016.

131. Moharaj R, Parker PG, Stephen LJ, Brodie MJ (2005) Levetiracetam in refractory epilepsy: a prospective observational study. Seizure 14:23-27.

132. Price MJ (2004) Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 20:33-36.

133. Enggaard TP, KiltgaardNA, SindrupSN (2006) Specific effect of levetiracetam on experimental human pain models," European Journal of Pain 10:193-198.

134. Gillyard M, Fuku K, LeducRotK, Matagne A (2011) Binding characteristics of brivaracem, aselective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsantproperties. European Journal of Pharmacology 646:36-44.

135. Suls A, Mullen SA, Weber YG, Verhaert K, Ceulemans B, et al. (2009) Paroxysmal exercise-induced dyskinesia and epilepsy issue to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain 131:1831-1844.

136. Suls A, De Jonghe P, Berkovic SF, Scheffer IE (2010) Absence epilepsies with new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 52:210-220.

137. Huang CW, Huang CC, Liu YC, Wu SN (2004) Inhibitory effect of lamotrigine on A-type potassium current in hippocampal neuron-derived H19-7 cells. Epilepsia 45:729-736.

138. Lee CY, Fu WM, Chen CC, Su MJ, LiouHH (2008) Lamotrigine inhibits postsynaptic AMPAReceptor and glutamate release in the dentate gyrus. Epilepsia49:888-897.

139. Jiang R, Goda Y, Geppert M, Missler M, Südhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24:1003-1016.